drugset / Trial / NCT03222427

A Study of LY3314814 in Healthy Participants

NCT03222427

Phase 1 Completed 8 enrolled AstraZeneca Eli Lilly and Company · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to measure how much LY3314814 gets into the bloodstream when it is given as a single dose by mouth and as an intravenous (IV) infusion over two hours. The study will last at least two weeks for each participant, not including screening.

Timeline

Start
2018-01-15
Primary completion
2018-02-16
Completion
2018-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanabecestat Small molecule 100 ug Oral
Subject Lanabecestat Small molecule 50 mg Oral

Indications

No indication recorded.